Retatrutide (triple GLP-1/GIP/glucagon receptor agonist): At 24 weeks, the 12 mg dose achieved 17.5% body weight reduction
Prescription GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are injectable drugs that have undergone extensive clinical trial processes and regulatory review
9 Another statistical analysis of 21 studies found that bariatric surgery resulted in decreases in hirsutism, menstrual irregularity, infertility, type 2 diabetes, high blood pressure, and depression
19,20 Retatrutide, a triple GLP-1/GIP/glucagon agonist, has demonstrated the greatest reported efficacy to date, with weight loss reaching approximately 24.2% in adult clinical trials
Some patients with severe IBS find oral medications more predictable than weekly injections because the medication level rises and falls more gradually